To explore the relevance of our findings in models that were more clinically relevant, we next investigated the role of FGD3 in the response to doxorubicin and ErSO in two breast cancer patient-derived organoids (PDOs), S021 and S035. Here, FGD3 is linked to breast carcinoma.